Biofrontera raised 3 Million Euro in capital round
02-Jun-2009
- Germany
"For successful progression of the clinical trials with our product candidates the fresh capital is utterly important. With the current constraints of the capital markets money raising is extremely difficult for technology companies. We are very happy about the successful completion of this capital round, illustrating the trust of our old and new shareholders in the company", stated Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.